Akari Therapeutics focusing on developing precision ADCs for cancer treatment, seeking non-dilutive capital.

From GlobeNewswire: 2025-04-16 08:00:00

Akari Therapeutics is making strides in developing next-generation precision Antibody Drug Conjugates (ADCs) for multiple cancer types. Their lead program, AKTX-101, is aimed at treating solid tumors. The company’s platform technology enables the creation of novel ADC candidates for various cancers. They are seeking non-dilutive capital opportunities and have enough cash to fund operations until September 2025.

In 2024, Akari completed a merger with Peak Bio Inc. and is focusing on advancing their precision ADC pipeline candidates. They have appointed new leadership to drive success and are working on novel anti-cancer payloads. AKTX-101, their lead candidate, utilizes a unique Spliceosome Inhibitor with multiple anti-tumor mechanisms, offering potential benefits over current ADCs.

Akari is gearing up for key milestones with their Precision Bi-Functional ADC Platform. They plan to present preclinical data, continue studies on AKTX-101, and seek licensing partners. Efforts are also ongoing to secure non-dilutive capital for legacy pipeline assets. Financially, the company reported a net loss in 2024 due to merger and restructuring costs, but they have enough cash to sustain operations into September 2025.

The company’s consolidated balance sheets show current assets of $2.6 million and total assets of $50.6 million as of December 31, 2024. Operating expenses in 2024 amounted to $21.6 million, with research and development expenses totaling $7.0 million. Despite challenges, Akari remains optimistic about advancing their product candidates and securing business development partnerships to drive growth.



Read more at GlobeNewswire:: Akari Therapeutics Reports Full Year 2024 Financial Results